vTv Therapeutics (VTVT) Income from Continuing Operations (2014 - 2026)

vTv Therapeutics has disclosed Income from Continuing Operations across 13 years of filings, most recently posting 24134000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 24134000.0, up 488.19% year-over-year; the trailing twelve-month figure through Mar 2026 was 729000.0 (up 96.82% YoY), and the FY2025 annual result was 31080000.0, down 36.89% from the prior year.
• Income from Continuing Operations came in at 24134000.0 for Q1 2026 at vTv Therapeutics, up from 7138000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 24134000.0 in Q1 2026 to a low of 10345000.0 in Q3 2025.
• The 5-year median for Income from Continuing Operations is 6090000.0 (2022), against an average of 4746470.59.
• Across the five-year window, Income from Continuing Operations sank 386.44% in 2022 and jumped 488.19% in 2026, its largest moves.
• vTv Therapeutics' Income from Continuing Operations stood at 6090000.0 in 2022, then advanced by 27.08% to 4441000.0 in 2023, then rose by 0.09% to 4437000.0 in 2024, then slumped by 60.87% to 7138000.0 in 2025, then jumped by 438.11% to 24134000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 24134000.0 (Q1 2026), 7138000.0 (Q4 2025), and 10345000.0 (Q3 2025), per Business Quant data.